01 diciembre 2015

JACC: Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF. Warfarin Versus NOACs Versus LAA Closure

Vivek Y. Reddy, MD∗; Ronald L. Akehurst, MFPHM†; Shannon O. Armstrong, BA‡; Stacey L. Amorosi, MA§; Stephen M. Beard, MSc‖; David R. Holmes, Jr., MD¶

Background: Left atrial appendage closure (LAAC) and nonwarfarin oral anticoagulants (NOACs) have emerged as safe and effective alternatives to warfarin for stroke prophylaxis in patients with nonvalvular atrial fibrillation (AF).

01 diciembre 2015

JACC: Outcome and Impact of Aortic Valve Replacement in Patients With Preserved LVEF and Low-Gradient Aortic Stenosis

Victor Dayan, MD, PhD∗; Gustavo Vignolo, MD∗; Julien Magne, PhD†; Marie-Annick Clavel, DVM, PhD‡; Dania Mohty, MD†; Philippe Pibarot, DVM, PhD‡

Background: Low mean transvalvular gradient (<40 mm Hg) and small aortic valve area (<1.0 cm2) in patients with aortic stenosis (AS) and preserved left ventricular ejection fraction raises uncertainty about the actual severity of the stenosis and survival benefit of aortic valve replacement (AVR).

01 diciembre 2015

JACC: Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease

Daniel J. Friedman, MD∗; Jagmeet P. Singh, MD, DPhil†; Jeptha P. Curtis, MD‡; W.H. Wilson Tang, MD§; Haikun Bao, PhD‡; Erica S. Spatz, MD, MHS‡; Adrian F. Hernandez, MD, MHS∗,‖; Uptal D. Patel, MD‖,¶; Sana M. Al-Khatib, MD, MHS∗,‖

Background: Patients with moderate-to-severe chronic kidney disease (CKD) are poorly represented in clinical trials of cardiac resynchronization therapy (CRT).

01 diciembre 2015

JACC: Annual Outcomes With Transcatheter Valve Therapy. From the STS/ACC TVT Registry

David R. Holmes, Jr., MD∗; Rick A. Nishimura, MD∗; Frederick L. Grover, MD†; Ralph G. Brindis, MD, MPH‡; John D. Carroll, MD†; Fred H. Edwards, MD§; Eric D. Peterson, MD, MPH‖; John S. Rumsfeld, MD, PhD¶; David M. Shahian, MD#; Vinod H. Thourani, MD∗∗; E. Murat Tuzcu, MD††; Sreekanth Vemulapalli, MD‖; Kathleen Hewitt, RN, MSN‡‡; Joan Michaels, RN, MSNm‡‡; Susan Fitzgerald, RN, MS‡‡; Michael J. Mack, MD§§

Background: The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry has been a joint initiative of the STS and the ACC in concert with multiple stakeholders. The TVT Registry has important information regarding patient selection, delivery of care, science, education, and research in the field of structural valvular heart disease.

01 diciembre 2015

JACC: Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis

Tomohiko Taniguchi, MD∗; Takeshi Morimoto, MD, MPH†; Hiroki Shiomi, MD∗; Kenji Ando, MD‡; Norio Kanamori, MD§; Koichiro Murata, MD‖; Takeshi Kitai, MD¶; Yuichi Kawase, MD#; Chisato Izumi, MD∗∗; Makoto Miyake, MD∗∗; Hirokazu Mitsuoka, MD††; Masashi Kato, MD‡‡; Yutaka Hirano, MD§§; Shintaro Matsuda, MD∗; Kazuya Nagao, MD‖‖; Tsukasa Inada, MD‖‖; Tomoyuki Murakami, MD¶¶; Yasuyo Takeuchi, MD##; Keiichiro Yamane, MD∗∗∗; Mamoru Toyofuku, MD†††; Mitsuru Ishii, MD‡‡‡; Eri Minamino-Muta, MD∗; Takao Kato, MD∗; Moriaki Inoko, MD§§§; Tomoyuki Ikeda, MD‖‖‖; Akihiro Komasa, MD¶¶¶; Katsuhisa Ishii, MD¶¶¶; Kozo Hotta, MD###; Nobuya Higashitani, MD∗∗∗∗; Yoshihiro Kato, MD††††; Yasutaka Inuzuka, MD‡‡‡‡; Chiyo Maeda, MD§§§§; Toshikazu Jinnai, MD∗∗∗∗; Yuko Morikami, MD‖‖‖‖; Ryuzo Sakata, MD¶¶¶¶; Takeshi Kimura, MD∗

Background: Current guidelines generally recommend watchful waiting until symptoms emerge for aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis (AS).

01 diciembre 2015

JACC: Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. 5-Year Results of EVEREST II

Ted Feldman, MD∗; Saibal Kar, MD†; Sammy Elmariah, MD, MPH‡,§; Steven C. Smart, MD∗; Alfredo Trento, MD‖; Robert J. Siegel, MD†; Patricia Apruzzese, MS§; Peter Fail, MD¶; Michael J. Rinaldi, MD#; Richard W. Smalling, MD, PhD∗∗; James B. Hermiller, MD††; David Heimansohn, MD‡‡; William A. Gray, MD§§; Paul A. Grayburn, MD‖‖; Michael J. Mack, MD¶¶; D. Scott Lim, MD##; Gorav Ailawadi, MD∗∗∗; Howard C. Herrmann, MD†††; Michael A. Acker, MD‡‡‡; Frank E. Silvestry, MD†††; Elyse Foster, MD§§§; Andrew Wang, MD‖‖‖; Donald D. Glower, MD¶¶¶; Laura Mauri, MD§,###

Background: In EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR) with a novel percutaneous device showed superior safety compared with surgery, but less effective reduction in MR at 1 year.

01 diciembre 2015

JACC: Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. The Randomized BRAVO-3 Trial

George D. Dangas, MD, PhD∗; Thierry Lefèvre, MD†; Christian Kupatt, MD‡; Didier Tchetche, MD§; Ulrich Schäfer, MD‖; Nicolas Dumonteil, MD¶; John G. Webb, MD#; Antonio Colombo, MD∗∗; Stephan Windecker, MD††; Jurriën M. ten Berg, MD, PhD‡‡; David Hildick-Smith, MD§§; Roxana Mehran, MD∗; Peter Boekstegers, MD‖‖; Axel Linke, MD¶¶; Christophe Tron, MD##; Eric Van Belle, MD, PhD∗∗∗; Anita W. Asgar, MD†††; Andreas Fach, MD‡‡‡; Raban Jeger, MD§§§; Gennaro Sardella, MD‖‖‖; Hans Ulrich Hink, MD¶¶¶; Oliver Husser, MD, PhD###; Eberhard Grube, MD∗∗∗∗; Efthymios N. Deliargyris, MD††††; Ilknur Lechthaler‡‡‡‡; Debra Bernstein, PhD††††; Peter Wijngaard, PhD‡‡‡‡; Prodromos Anthopoulos, MD‡‡‡‡; Christian Hengstenberg, MD§§§§

Background: Anticoagulation is required during transcatheter aortic valve replacement (TAVR) procedures. Although an optimal regimen has not been determined, heparin is mainly used. Direct thrombin inhibition with bivalirudin may be an effective alternative to heparin as the procedural anticoagulant agent in this setting.

01 diciembre 2015

JACC: Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy. The VISTA Randomized Multicenter Trial

Luigi Di Biase, MD, PhD∗,†,‡,§; J. David Burkhardt, MD∗; Dhanujaya Lakkireddy, MD‖; Corrado Carbucicchio, MD¶; Sanghamitra Mohanty, MD∗; Prasant Mohanty, MBBS, MPH∗; Chintan Trivedi, MD, MBBS∗; Pasquale Santangeli, MD§,#; Rong Bai, MD∗,∗∗; Giovanni Forleo, MD††; Rodney Horton, MD∗; Shane Bailey, MD∗; Javier Sanchez, MD∗; Amin Al-Ahmad, MD∗; Patrick Hranitzky, MD∗; G. Joseph Gallinghouse, MD∗; Gemma Pelargonio, MD‡‡; Richard H. Hongo, MD§§; Salwa Beheiry, RN§§; Steven C. Hao, MD§§; Madhu Reddy, MD‖; Antonio Rossillo, MD‖‖; Sakis Themistoclakis, MD‖‖; Antonio Dello Russo, MD¶; Michela Casella, MD¶; Claudio Tondo, MD¶; Andrea Natale, MD∗,‡,§§,¶¶,##,∗∗∗,†††

Background: Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown.

01 enero 2016

JACC: Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement

Matthew R. Reynolds, MD, MSc∗,†; Yang Lei, MSc‡,§; Kaijun Wang, PhD‡; Khaja Chinnakondepalli, MS‡; Katherine A. Vilain, MPH‡; Elizabeth A. Magnuson, ScD‡,‖; Benjamin Z. Galper, MD, MPH¶; Christopher U. Meduri, MD, MPH#; Suzanne V. Arnold, MD, MHA‡,‖; Suzanne J. Baron, MD, MSc‡,‖; Michael J. Reardon, MD∗∗; David H. Adams, MD††; Jeffrey J. Popma, MD‡‡; David J. Cohen, MD, MSc‡,‖

Background: Previous studies of the cost-effectiveness of transcatheter aortic valve replacement (TAVR) have been based primarily on a single balloon-expandable system.

01 enero 2016

JACC: Myocardial Infarction Alters Adaptation of the Tethered Mitral Valve

Jacob P. Dal-Bianco, MD∗,‡; Elena Aikawa, MD, PhD‡,§; Joyce Bischoff, PhD‡,‖,¶; J. Luis Guerrero, BS†; Jesper Hjortnaes, MD§; Jonathan Beaudoin, MD∗,‡; Catherine Szymanski, MD∗,‡; Philipp E. Bartko, MD, PhD∗; Margo M. Seybolt, BS†; Mark D. Handschumacher, BS∗; Suzanne Sullivan, BS†; Michael L. Garcia, MA†; Adam Mauskapf, BA†; James S. Titus, BS†; Jill Wylie-Sears, MS‖; Whitney S. Irvin, MS§; Miguel Chaput, MD∗,‡; Emmanuel Messas, MD, PhD‡,#; Albert A. Hagège, MD, PhD‡,#; Alain Carpentier, MD, PhD‡,#; Robert A. Levine, MD∗,‡,#

Background: In patients with myocardial infarction (MI), leaflet tethering by displaced papillary muscles induces mitral regurgitation (MR), which doubles mortality. Mitral valves (MVs) are larger in such patients but fibrosis sets in counterproductively. The investigators previously reported that experimental tethering alone increases mitral valve area in association with endothelial-to-mesenchymal transition.

01 febrero 2016

JACC: Effect of Recurrent Mitral Regurgitation Following Degenerative Mitral Valve Repair. Long-Term Analysis of Competing Outcomes

Rakesh M. Suri, MD, DPhila; Marie-Annick Clavel, DVM, PhDb,c; Hartzell V. Schaff, MDa; Hector I. Michelena, MDb; Marianne Huebner, PhDd; Rick A. Nishimura, MDb; Maurice Enriquez-Sarano, MDd

Background: The risk for and consequences of recurrent mitral regurgitation (MR) following degenerative mitral valve repair are poorly understood.

01 febrero 2016

JACC: Incidence, Timing, and Predictors of Valve Hemodynamic Deterioration After Transcatheter Aortic Valve Replacement. Multicenter Registry

Maria Del Trigo, MDa; Antonio J. Muñoz-Garcia, MDb; Harindra C. Wijeysundera, MDc; Luis Nombela-Franco, MDd; Asim N. Cheema, MDe; Enrique Gutierrez, MDf; Vicenç Serra, MDg; Joelle Kefer, MD, PhDh; Ignacio J. Amat-Santos, MDi; Luis M. Benitez, MDj; Jumana Mewa, MDc; Pilar Jiménez-Quevedo, MD, PhDd; Sami Alnasser, MDe; Bruno Garcia del Blanco, MDg; Antonio Dager, MDj; Omar Abdul-Jawad Altisent, MDa; Rishi Puri, MBBS, PhDa; Francisco Campelo-Parada, MDa; Abdellaziz Dahou, MDa; Jean-Michel Paradis, MDa; Eric Dumont, MDa; Philippe Pibarot, DVM, PhDa; Josep Rodés-Cabau, MDa

Background: Scarce data exist on the incidence of and factors associated with valve hemodynamic deterioration (VHD) after transcatheter aortic valve replacement (TAVR).

01 febrero 2016

JACC: A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis. 5-Year Follow-Up

Patrick W. Serruys, MD, PhDa; John Ormiston, MBChB, PhDb; Robert-Jan van Geuns, MD, PhDc; Bernard de Bruyne, MD, PhDd; Dariusz Dudek, MDe; Evald Christiansen, MDf; Bernard Chevalier, MDg; Pieter Smits, MD, PhDh; Dougal McClean, MDi; Jacques Koolen, MD, PhDj; Stephan Windecker, MDk; Robert Whitbourn, MDl; Ian Meredith, MD, PhDm; Luc Wasungu, PhDn; Divine Ediebah, MSn; Susan Veldhof, RNn; Yoshinobu Onuma, MD, PhDc

Background: Long-term benefits of coronary stenosis treatment with an everolimus-eluting bioresorbable scaffold are unknown.

01 febrero 2016

JACC: Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents. 5-Year Results From SORT OUT IV

Lisette Okkels Jensen, MD, DMSci, PhDa; Per Thayssen, MD, DMScia; Evald Høj Christiansen, MD, PhDb; Michael Maeng, MD, PhDb; Jan Ravkilde, MD, DMScic; Knud Nørregaard Hansen, MDa; Henrik Steen Hansen, MD, DMScia; Lars Krusell, MDb; Anne Kaltoft, MD, PhDb; Hans Henrik Tilsted, MDc; Klara Berencsi, MScd; Anders Junker, MD, PhDa; Jens Flensted Lassen, MD, PhDb

Background: Long-term safety and efficacy for everolimus-eluting stents (EES) versus those of sirolimus-eluting stents (SES) are unknown.

01 febrero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Impact of intravascular ultrasound on the long-term clinical outcomes in the treatment of coronary ostial lesions

Yogesh Patel MD, Jeremiah P. Depta MD, MPHS, Jayendrakumar S. Patel MD, Shriti K. Masrani MD, Eric Novak MS, Alan Zajarias MD, Howard I. Kurz MD, John M. Lasala MD, PhD, Richard G. Bach MD andJasvindar Singh MD*

Objectives: To evaluate the long-term outcomes of patients with ostial lesions who underwent percutaneous coronary intervention (PCI) with and without the use of intravascular ultrasound (IVUS).